Mirion Technologies
Supplies radiation measurement and safety systems for nuclear operations, cancer care, laboratories, and defense.
Something off on this page? Send us feedback.
Profile
Sells radiation detection, monitoring, analysis, and safety systems through Nuclear & Safety and Medical. Revenue comes from instruments, software, services, and recurring calibration or replacement work spanning nuclear-plant lifecycles, laboratory and defense applications, radiation-therapy quality assurance, nuclear medicine, and worker dosimetry.
Supplies radiation detection, measurement, and monitoring products, software, and services through Nuclear & Safety and Medical. Nuclear & Safety covers reactor instrumentation across construction, operation, maintenance, and decommissioning, plus laboratory analysis, defense detection, regulatory compliance, and engineered components. Medical provides radiation-therapy quality assurance, nuclear-medicine products, and occupational dosimetry.
Serves utilities, reactor developers, hospitals, cancer centers, laboratories, governments, and militaries across North America, Europe, and Asia. Long-lived installed equipment creates replacement, calibration, upgrade, and service work; Certrec and Paragon extend the nuclear portfolio into licensing and obsolescence management.
Competes on reliability, technical qualification, and support in markets governed by strict specifications. Nuclear demand follows plant construction, operating-life extensions, maintenance, and decommissioning; medical demand depends on provider budgets, reimbursement, and evolving safety standards.
Company facts
Key statistics
Year to date −39.7% · Average volume (30d) 3.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 10, 2026 | Morgan Stanley | Target | $25 | $23 | |
| Jul 30, 2026 | Northland Securities | Target | $29 | $24 | |
| Jul 29, 2026 | Goldman Sachs | Reiterate | Buy | $25 | $23 |
| Jul 13, 2026 | Morgan Stanley | Reiterate | Equal Weight | $27 | $25 |
| Jul 10, 2026 | Goldman Sachs | Reiterate | Buy | $29 | $25 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $0.10 | $0.12 | +16.1% | $269.3M | $266.8M | −0.9% | −13.22% |
| Apr 28, 2026Q1 FY26 | $0.10 | $0.10 | 0.0% | $244.8M | $257.6M | +5.2% | −0.11% |
| Feb 10, 2026Q4 FY25 | $0.16 | $0.15 | −6.3% | $280.3M | $277.4M | −1.0% | −10.20% |
| Oct 28, 2025Q3 FY25 | $0.11 | $0.12 | +9.1% | $281.2M | $223.1M | −20.7% | +18.10% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $202.0M | $222.9M | $223.1M | $277.4M | $257.6M | $266.8M | |
| Gross profit | $96.1M | $102.7M | $104.5M | $135.3M | $119.1M | $133.1M | |
| Operating income | $8.7M | $9.9M | $7.4M | $25.5M | $3.7M | $17.9M | |
| Net income | $300.0K | $8.3M | $2.9M | $17.3M | −$3.4M | $7.7M | |
| Diluted EPS | $0.00 | $0.03 | $0.01 | $0.07 | −$0.01 | $0.03 | |
| Gross margin | 47.6% | 46.1% | 46.8% | 48.8% | 46.2% | 49.9% | |
| Operating margin | 4.3% | 4.4% | 3.3% | 9.2% | 1.4% | 6.7% |
Fiscal years (4-quarter sums)FY21 $668.3M · FY22 $717.8M · FY23 $800.9M · FY24 $860.8M · FY25 $925.4M
Revenue by product · Q1 FY26
Revenue by geography · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $425.3M · Total debt $1.23B · Total assets $3.52B · Shareholders' equity $1.83B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 243.28M · Float 223.97M · 92.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 38.26M | 15.73% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 18.18M | 7.47% | 13F | Aug 13, 2026 |
| T. Rowe Price Investment Management, Inc. | 14.29M | 5.87% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 10.61M | 4.36% | 13F | Aug 13, 2026 |
| Goldman Sachs Group Inc | 10.41M | 4.28% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | Christopher A. Moore | officer: Chief Accounting Officer (PAO) | −8,400 | $19.64 |
| Dec 10, 2025 | Lawrence D. Kingsley | director | −350,000 | $24.73 |
| Nov 21, 2025 | Lawrence D. Kingsley | director | −300,000 | $23.83 |
| Nov 10, 2025 | Emmanuelle Lee | officer: Chief Legal Officer | −12,500 | $27.41 |
| Nov 11, 2025 | Loic Eloy | officer: Nuclear & Safety President | −45,000 | $27.24 |
Peers
- Thermo Fisher Scientific
Broadest direct overlap in radiation detection and dosimetry
- Fortive
Direct dosimetry and safety-monitoring peer through Landauer
- AMETEK
ORTEC overlaps in nuclear detectors and spectroscopy systems
- Teledyne Technologies
FLIR overlaps in radiological search and CBRN defense sensing
- Curtiss-Wright
Nuclear plant safety systems overlap after Ultra Energy deal
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mirion Technologies | $14.66 | +2.02% | $3.50B | 153.8 | 24.5 | 3.4 | +19.7% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Fortive | $59.69 | 0.00% | $18.03B | 35.1 | 19.2 | 4.2 | −27.8% |
| AMETEK | $236.99 | +0.31% | $54.15B | 34.5 | 27.1 | 6.9 | +15.0% |
| Teledyne Technologies | $621.96 | +0.02% | $28.83B | 30.0 | 24.4 | 4.5 | +9.8% |
| Curtiss-Wright | $596.37 | −0.07% | $22.03B | 41.0 | 36.9 | 6.0 | +5.4% |
| Median | 34.5 | 24.4 | 5.0 | +9.8% |